Jaguar Health CEO, Board Members, Other C-Suite Members, and Institutional and Accredited Investors Invest in $3.448 Million Bridge Financing Priced At-The-Market Under Nasdaq Rules
Jaguar Health (NASDAQ:JAGX) has secured a $3.448 million bridge financing through convertible promissory notes in a private placement priced at-the-market under Nasdaq rules. The company's CEO Lisa Conte, three board members, seven C-suite executives, and selected institutional and accredited investors participated in the financing.
The notes feature a 3-month maturity with a 6% annual interest rate and are immediately convertible into common stock. Additionally, investors will receive unregistered warrants exercisable immediately with a five-year expiration term. The offering is expected to close around March 27, 2025.
H.C. Wainwright & Co. serves as the exclusive placement agent. The proceeds will be used for working capital and general corporate purposes. The securities are being offered under Section 4(a)(2) of the Securities Act and Regulation D, with the company agreeing to file a resale registration statement for the underlying shares.
Jaguar Health (NASDAQ:JAGX) ha ottenuto un finanziamento ponte di 3,448 milioni di dollari attraverso note promissorie convertibili in un collocamento privato a prezzo di mercato secondo le regole Nasdaq. Il CEO dell'azienda, Lisa Conte, tre membri del consiglio, sette dirigenti di alto livello e investitori istituzionali e accreditati selezionati hanno partecipato al finanziamento.
Le note hanno una scadenza di 3 mesi con un tasso d'interesse annuale del 6% e sono immediatamente convertibili in azioni ordinarie. Inoltre, gli investitori riceveranno warrant non registrati esercitabili immediatamente con una scadenza di cinque anni. Si prevede che l'offerta si chiuda intorno al 27 marzo 2025.
H.C. Wainwright & Co. funge da agente di collocamento esclusivo. I proventi saranno utilizzati per il capitale circolante e scopi aziendali generali. I titoli sono offerti ai sensi della Sezione 4(a)(2) del Securities Act e della Regolamentazione D, con l'azienda che si impegna a presentare una dichiarazione di registrazione per la rivendita delle azioni sottostanti.
Jaguar Health (NASDAQ:JAGX) ha asegurado un financiamiento puente de 3,448 millones de dólares a través de notas promisorías convertibles en una colocación privada a precio de mercado bajo las reglas de Nasdaq. La CEO de la compañía, Lisa Conte, tres miembros de la junta, siete ejecutivos de nivel C e inversores institucionales y acreditados seleccionados participaron en el financiamiento.
Las notas tienen un vencimiento de 3 meses con un tasa de interés anual del 6% y son inmediatamente convertibles en acciones comunes. Además, los inversores recibirán warrants no registrados que se pueden ejercer de inmediato con un plazo de expiración de cinco años. Se espera que la oferta se cierre alrededor del 27 de marzo de 2025.
H.C. Wainwright & Co. actúa como agente de colocación exclusivo. Los ingresos se utilizarán para capital de trabajo y propósitos corporativos generales. Los valores se ofrecen bajo la Sección 4(a)(2) de la Ley de Valores y la Regulación D, con la empresa comprometiéndose a presentar una declaración de registro de reventa para las acciones subyacentes.
재규어 헬스 (NASDAQ:JAGX)는 나스닥 규정에 따라 시장 가격으로 진행된 사모 배치에서 전환사채를 통해 344만 8천 달러의 브릿지 자금을 확보했습니다. 회사의 CEO인 리사 콘테, 이사회 3명, C-suite 임원 7명, 그리고 선정된 기관 및 인증된 투자자들이 자금 조달에 참여했습니다.
이 노트는 3개월 만기와 연 6% 이자율을 특징으로 하며, 즉시 보통주로 전환 가능합니다. 또한, 투자자들은 즉시 행사할 수 있는 등록되지 않은 워런트를 5년 만기로 받게 됩니다. 이 제안은 2025년 3월 27일경에 마감될 것으로 예상됩니다.
H.C. Wainwright & Co.는 독점 배치 에이전트로 활동합니다. 수익금은 운영 자본과 일반 기업 목적에 사용될 예정입니다. 이 증권은 증권법 제4(a)(2)조 및 규정 D에 따라 제공되며, 회사는 기초 주식의 재판매 등록서를 제출하기로 약속했습니다.
Jaguar Health (NASDAQ:JAGX) a sécurisé un financement relais de 3,448 millions de dollars par le biais de billets à ordre convertibles dans le cadre d'un placement privé à prix de marché conformément aux règles de Nasdaq. La PDG de l'entreprise, Lisa Conte, trois membres du conseil d'administration, sept cadres supérieurs et des investisseurs institutionnels et accrédités sélectionnés ont participé au financement.
Les billets ont une échéance de 3 mois avec un taux d'intérêt annuel de 6% et sont immédiatement convertibles en actions ordinaires. De plus, les investisseurs recevront des bons de souscription non enregistrés exerçables immédiatement avec une durée d'expiration de cinq ans. La clôture de l'offre est prévue aux alentours du 27 mars 2025.
H.C. Wainwright & Co. agit en tant qu'agent de placement exclusif. Les produits seront utilisés pour le fonds de roulement et les objectifs généraux de l'entreprise. Les titres sont offerts en vertu de la section 4(a)(2) de la loi sur les valeurs mobilières et de la réglementation D, l'entreprise s'engage à déposer une déclaration d'enregistrement pour la revente des actions sous-jacentes.
Jaguar Health (NASDAQ:JAGX) hat eine Brückenfinanzierung in Höhe von 3,448 Millionen Dollar durch wandelbare Schuldverschreibungen in einer privaten Platzierung zu Marktpreisen gemäß den Nasdaq-Vorgaben gesichert. Die CEO des Unternehmens, Lisa Conte, drei Vorstandsmitglieder, sieben Führungskräfte der C-Ebene sowie ausgewählte institutionelle und akkreditierte Investoren haben an der Finanzierung teilgenommen.
Die Schuldverschreibungen haben eine Laufzeit von 3 Monaten und einen Jahreszinssatz von 6% und sind sofort in Stammaktien umwandelbar. Darüber hinaus erhalten die Investoren unverzeichnete Warrants, die sofort ausgeübt werden können und eine Laufzeit von fünf Jahren haben. Es wird erwartet, dass das Angebot um den 27. März 2025 geschlossen wird.
H.C. Wainwright & Co. fungiert als exklusiver Platzierungsagent. Die Erlöse werden für Betriebskapital und allgemeine Unternehmenszwecke verwendet. Die Wertpapiere werden gemäß Abschnitt 4(a)(2) des Wertpapiergesetzes und der Regelung D angeboten, wobei das Unternehmen zustimmt, eine Verkaufsregistrierungserklärung für die zugrunde liegenden Aktien einzureichen.
- Insider participation demonstrates management confidence
- Secured immediate working capital of $3.448 million
- At-the-market pricing aligns with current market value
- Short-term 3-month maturity indicates urgent capital needs
- Potential dilution from convertible notes and warrants
- High-cost financing with 6% interest rate plus warrants
SAN FRANCISCO, CA / ACCESS Newswire / March 26, 2025 / Jaguar Health, Inc.(NASDAQ:JAGX) ("Jaguar" or "the Company"), announced today that Jaguar's president and chief executive officer Lisa Conte, three other members of the Company's board of directors, and seven other C-suite and senior executives of Jaguar along with selected institutional and accredited investors (each, an "Investor") entered into securities purchase agreements, pursuant to which the Company will issue up to
The Company will use the proceeds for working capital and other general corporate purposes. In addition, the Company has agreed to issue to the Investors unregistered warrants, which will be exercisable immediately and will expire on the earlier of (i) five years from the date of issuance, (ii) the consummation of a fundamental transaction and (iii) the consummation of a liquidation event.
The offering is expected to close on or about March 27, 2025, subject to satisfaction of customary closing conditions. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.
The securities described above are being offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the "Securities Act"), and/or Regulation D promulgated thereunder and, along with the shares of common stock underlying the convertible notes and warrants, have not been registered under the Securities Act, or applicable state securities laws. Accordingly, such securities may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws. Pursuant to a registration rights agreement with investors, the Company has agreed to file a resale registration statement covering the resale of the shares of common stock underlying the convertible notes and warrants.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
About the Jaguar Health Family of Companies
Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Jaguar family company Napo Pharmaceuticals (Napo) focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Napo's crofelemer is FDA-approved under the brand name Mytesi® for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan and/or rare diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar's Entheogen Therapeutics Initiative (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications.
For more information about:
Jaguar Health, visit https://jaguar.health
Napo Pharmaceuticals, visit www.napopharma.com
Napo Therapeutics, visit napotherapeutics.com
Magdalena Biosciences, visit magdalenabiosciences.com
Visit the Make Cancer Less Shitty patient advocacy program on Bluesky, X, Facebook & Instagram
Forward-Looking Statements
Certain statements in this press release constitute "forward-looking statements." These include statements regarding the expected closing of the offering and the intended use of proceeds from the offering. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
Contact:
hello@jaguar.health
Jaguar-JAGX
SOURCE: Jaguar Health, Inc.
View the original press release on ACCESS Newswire
FAQ
What are the key terms of JAGX's March 2025 bridge financing?
How much insider participation was there in JAGX's March 2025 financing?
What is the purpose of JAGX's $3.448M bridge financing?
When will JAGX's March 2025 bridge financing close?
